Delivery Order SPE2DB22D2006-SPE2DB24FV8TT
- Not listed
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distributor Amerisourcebergen Corporation, to provide the HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical product. The $3,943.20 award has a completion date of February 6, 2024. Amerisourcebergen Drug Corp, a for-profit organization, serves as a prime contractor to DLA Troop Support Medical, supplying pharmaceuticals and medical supplies in...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical products. The order has a completion date of February 8, 2024 and a potential value of $1,577.28. Amerisourcebergen Drug Corp is the prime contractor on this delivery order, which is not associated with any set-aside designation. Additionally, Amerisourcebergen Drug Corp holds...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $7,148.05 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide the HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical product. The contract has an ultimate completion date of March 25, 2024 and does not utilize any set-aside designation. Amerisourcebergen Drug Corp holds an indefinite delivery contract with DLA valued up to $999,999,999.00 through December 31,...
- The U.S. Department of Defense's Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceutical products. The delivery order, valued at $2,365.92, has a completion date of February 23, 2024. AmerisourceBergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) awarded by DLA, valued up to $999,999,999.00 with a...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. The $1,577.28 award has a completion date of February 13, 2024. Amerisourcebergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) with DLA, valued at up to $999,999,999.00, that serves as the primary vehicle for the company to deliver pharmaceutical products...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $18,927.36 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML syringes. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary contract...
- Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distribution company Amerisourcebergen Corporation, has been awarded a $78,864.00 firm fixed price delivery order contract by the Defense Logistics Agency (DLA) to provide HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceuticals. This delivery order does not have a set-aside designation and is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 that Amerisourcebergen Drug Corp holds...
- The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $3,154.56 to AmerisourceBergen Drug Corp's Corporate Office division. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, which has a ceiling value of up to $999,999,999 and is in effect through December 2025. The...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The $41,926.39 order is for HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a pharmaceutical product, with a completion date of February 15, 2024. Amerisourcebergen Drug Corp is a for-profit organization that serves as a prime contractor providing a wide range of pharmaceutical products and medical supplies to U.S. government agencies,...
- The Department of Defense's Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide HEPLISAV-B 20 MCG/0.5 ML syringes. The $113,046.95 contract has a completion date of March 31, 2023 and does not have a set-aside designation. Amerisourcebergen Drug Corp, as a prime contractor, has a history of supplying pharmaceuticals, medical supplies, and distribution services to DLA Troop...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB24FV8TTDelivery Order
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract valued at $78,864.00 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML. This delivery order is part of a larger indefinite delivery contract (IDC) awarded to Amerisourcebergen Drug Corp by DLA, valued up to $999,999,999.00 through December 31, 2025. The IDC serves as the primary contract vehicle for Amerisourcebergen to deliver pharmaceutical products and medical supplies to DLA Troop Support Medical facilities supporting the Department of Defense. No set-aside designation was used for this delivery order. Amerisourcebergen Corporation, through its Amerisourcebergen Drug Corp division, is a leading global pharmaceutical sourcing and distribution services company providing a wide range of products and services to U.S. government agencies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $78.9k | 3/13/24 |